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Abstract: Hypoplastic left heart syndrome (HLHS) is a clinically and
anatomically severe form of congenital heart disease (CHD). Although prior
studies suggest that HLHS has a complex genetic inheritance, its etiology
remains largely unknown. The goal of this study was to characterize a risk
gene in HLHS and its effect on HLHS etiology and outcome. We performed
next-generation sequencing on a multigenerational family with a high
prevalence of CHD/HLHS, identifying a rare variant in the α-myosin heavy
chain (MYH6) gene. A case-control study of 190 unrelated HLHS subjects was
then performed and compared with the 1000 Genomes Project. Damaging
MYH6 variants, including novel, missense, in-frame deletion, premature stop,
de novo, and compound heterozygous variants, were significantly enriched in
HLHS cases (P < 1 × 10−5). Clinical outcomes analysis showed reduced
transplant-free survival in HLHS subjects with damaging MYH6 variants (P < 1
× 10−2). Transcriptome and protein expression analyses with cardiac tissue
revealed differential expression of cardiac contractility genes, notably
upregulation of the β-myosin heavy chain (MYH7) gene in subjects with MYH6
variants (P < 1 × 10−3). We subsequently used patient-specific induced
pluripotent stem cells (iPSCs) to model HLHS in vitro. Early stages of in vitro
cardiomyogenesis in iPSCs derived from two unrelated HLHS families
mimicked the increased expression of MYH7 observed in vivo (P < 1 × 10−2),
while revealing defective cardiomyogenic differentiation. Rare, damaging
variants in MYH6 are enriched in HLHS, affect molecular expression of
contractility genes, and are predictive of poor outcome. These findings
indicate that the etiology of MYH6-associated HLHS can be informed using
iPSCs and suggest utility in future clinical applications.
Hypoplastic Left Heart Syndrome (HLHS) is a clinically and
anatomically severe form of congenital heart disease (CHD). HLHS,
characterized by hypoplasia of the ascending aorta and left ventricle, was first
described by Noonan and Nadas.32 HLHS accounts for as much as 4% of
subjects with CHD but is responsible for 15–25% of CHD-related mortality.3
The cause of HLHS is unknown in most cases.
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Evidence supporting a genetic basis for HLHS includes observations of
familial clustering and high heritability16 and concurrence with specific
chromosomal disorders such as Turner and Jacobsen syndrome. Variants in
genes such as GJA1,7 NKX2.5,10 NOTCH1,11 and most recently, myosin heavy
chain 6 (MYH6)38 as well as observations of syndromic or rare copy number
variants in cardiogenic genes13,14,39,41 have been associated with HLHS.
Increased frequency of left-ventricular outflow tract obstructions (LVOTO)
such as bicuspid aortic valve (BAV) and coarctation of the aorta (CoA) have
been noted in relatives of HLHS subjects.16,17,23,24,29 Although these studies
indicate an underlying genetic basis, known risk factors currently explain
<5% of HLHS etiology.16,17
In this study, next-generation sequencing of a multigenerational
CHD/HLHS family revealed a novel variant in the MYH6 gene. Although MYH6
variants have been previously associated with cardiac phenotypes,1,4,6,12,33,38
to better understand their role in HLHS we have employed a multifaceted
approach including a case-control association study, transcriptome analysis of
patient cardiac tissue, clinical outcomes, and the use of patient-specific
induced pluripotent stem cells (iPSCs) to model HLHS disease in vitro. Results
reveal that a significant percentage of HLHS patients have rare and damaging
MYH6 variants that impact the expression of other sarcomere genes and are
predictive of poor clinical outcomes. Moreover, experiments using patientderived cardiomyocytes indicate that HLHS may have a cardiomyocyteautonomous etiology that can be investigated via in vitro modeling with
iPSCs.

Methods
Study Participants
HLHS was strictly defined by atresia or stenosis of the aortic and
mitral valves and hypoplasia of the left ventricle and ascending aorta,
with intact ventricular septum.36 Subjects with complex cardiovascular
malformations combined with left ventricle hypoplasia (such as
unbalanced atrioventricular septal defects or double-outlet right
ventricle) were excluded. Subjects with known genetic syndromes
(Trisomy 18, 21, or Turner syndrome) or with extracardiac
malformations suggestive of a genetic syndrome were also excluded.
See supplementary methods: phenotyping cardiac malformations for
additional details.1 This study is in accordance with the principles
outlined in the Declaration of Helsinki and institutionally approved
research (IRB) protocols by the Children's Hospital of Wisconsin (CHW,
Milwaukee, WI). Subjects were consented through the CHD Tissue
Bank (IRB #CHW 06/229, GC 300) and the Wisconsin Pediatric Cardiac
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Registry (IRB #CHW 09/91, GC 889), IRB-approved research
databases housed at CHW prior to inclusion in the study.15,39 Both
biorepositories provided all DNA samples, as well as cardiac tissue,
from patients and family members, with associated clinical outcome
variables.

Multistage Approach to Investigate HLHS
Figure 1 depicts the multistage approach used in this study to
investigate the role of MYH6 in HLHS, as follows.

Fig. 1. Five-stage study design. Stage 1 analyzed the pedigree of family F MYH6R443P. Stage 2 was a case-control association study assessing rare α-myosin heavy
chain gene (MYH6) variants in 190 unrelated hypoplastic left heart syndrome (HLHS)
subjects. Stage 3 assessed the clinical outcome of MYH6 variant carriers compared
with non-MYH6 variant carriers. Stage 4 utilized transcriptome sequencing and
Western blotting to compare gene expression in HLHS subjects with and without MYH6
variants. Stage 5 employed induced pluripotent stem cells (iPSCs) to model HLHS
disease in 2 unrelated families with MYH6 variants.

Stage 1: Multigenerational HLHS family.
We used next-generation sequencing to evaluate a
multigenerational family (F MYH6-R443P) identified by a proband with
HLHS through the CHD Tissue Bank. Other family members had CHDs
affecting left-sided heart structures, including a second case of HLHS
as shown in the pedigree (Fig. 2). Whole genome sequencing (WGS)
was performed on the proband, affected sibling, father, and mother
(IV:3, IV:1, III:1, and III:2). Whole exome sequencing (WES) was
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performed on the paternal great aunt (II:4). For technical processing
and variant filtering see supplemental methods: next generation
sequencing and supplemental methods: additional stage 1 analysis.

Fig. 2. Pedigree of family MYH6: R443P, variant filtering scheme and MYH6 variants in
a case-control study. A: black squares and circles denote patients with left ventricular
outflow tract obstructions (LVOTO; III:1, III:9, IV:1, IV:3). Striping denotes
ventricular septal defect, unrelated heart defect to HLHS. Gray-shaded symbols denote
subjects with uncertain or no diagnosis of congenital heart disease (CHD). White
squares/circles denote patients without CHD. Genotypes denoted R443P indicate
heterozygous carriers of an MYH6 variant. WT, wild type; symbols without a genotype
are of unknown genotype. Squares, male; circles, female; triangles, fetal demise. B:
identification and filtering variants in affected siblings and a distant relative followed
by subtracting variants in the unaffected mother identified 20 candidate genes. Among
them, MYH6 was the only candidate highly expressed in the heart. C: loci of 19 distinct
rare MYH6 variants discovered in 190 HLHS subjects. Left to right: loci of variants in
the MYH6 gene encoding the head, neck, and coiled-coil (tail) regions of α-MHC
protein. Dots denote variants in HLHS subjects.

Stage 2: case-control association study.
DNA samples were obtained from 190 unrelated HLHS probands.
Control genomes were from the 1000 Genomes project (1,063
unrelated individuals of African, Amerindian, Asian, or European
descent).40 Rare, damaging variants (see supplemental methods: next
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generation sequencing) identified in candidate genes from Stage 1
were individually tested comparing carriers vs. noncarriers in HLHS
cases vs. controls (Fisher's exact test).

Stage 3: transplant-free survival analysis.
We defined clinical outcomes by comparing transplant-free
survival data of HLHS subjects with and without rare, damaging MYH6
variants. Poor outcome was defined as death or cardiac transplant.
Survival was assessed in subjects aged 6 yr or older using KaplanMeier curves; a Breslow (generalized Wilcoxon) statistic was used to
evaluate significance.

Stage 4: mRNA expression/protein expression.
Cardiac tissue discards from HLHS subjects undergoing surgery
were snap-frozen in liquid nitrogen and stored at −80°C until RNA or
protein isolation. Transcriptome sequencing and Western blot analysis
were performed as described in the supplementary appendix. Pairwise
analysis was performed, comparing subjects with and without rare,
damaging MYH6 variants matched by age, tissue type, and when
possible, by sex and cardiac anatomy (mitral and aortic valve)
(Supplemental Table S2). The same matched tissue pairings were also
analyzed by Western blot analysis.

Stage 5: HLHS modeling with iPSCs.
iPSC lines were generated from dermal fibroblasts donated by
two unrelated HLHS probands and their parents (two family trios),
denoted as families F MYH6-R443P and F MYH6-D588A, to the CHD
Tissue Bank. Fibroblasts were reprogrammed to pluripotent stem cells
using Sendai reprogramming (ReGen Theranostics, Rochester, MN),
after which they were returned to CHW (Milwaukee, WI) for
experimentation. iPSCs cultured under hypoxic conditions on matrigel
in mTeSR1 medium were judged pluripotent from morphological
appearance (Supplemental Fig. S3), percentages of cells exhibiting
positive Oct4 immunostaining (99–100%), being karyotypically normal
(Supplemental Fig. S3), and the ability to differentiate into multiple
lineages (definitive endoderm and cardiomyogenic mesoderm).21
Experimenters were blinded as to the identity of family members from
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whom each line was generated. Details are described in supplementary
materials: ipsc cardiomyocyte differentiation and in ipsc analysis.

Results
A five-stage approach was employed to elucidate the role of
MYH6 variants in HLHS. In stage 1, members of family F MYH6-R443P
were analyzed with next-generation sequencing identifying a rare
variant in the MYH6 gene. In stage 2, a case-control analysis
confirmed that rare, damaging MYH6 variants were highly enriched
among 190 unrelated HLHS subjects. Stage 3 determined the clinical
outcome of HLHS subjects with and without rare, damaging MYH6
variants. Stage 4 utilized transcriptome sequencing and Western blot
analysis to compare gene expression in HLHS subjects with and
without rare, damaging MYH6 variants. Stage 5 employed iPSCs to
model HLHS disease in two unrelated families with different rare,
damaging MYH6 variants.

Stage 1: Pedigree Analysis of Family F MYH6-R443P
In family F MYH6-R443P (Fig. 2A) four members with LVOTO were
identified. The father (III.1) had CoA, and two children with LVOTO,
one of whom is an HLHS proband (IV.3) and the other (IV.1), had
double outlet right ventricle with unbalanced atrioventricular canal and
hypoplastic left ventricle. A deceased distant relative had a history of
HLHS (II:4). One relative had an unrelated heart defect,
perimembranous ventricular septal defect (IV:4). Identification and
filtering of variants in affected siblings (IV:1 and IV:3) and great aunt
(II:4), followed by subtracting variants identified in the unaffected
mother (III.2), identified 20 candidate genes (See supplemental
methods, next-generation sequencing, and Supplemental Table S1).
Among these, MYH6 was the only gene with a known cardiac
association that is highly expressed in the heart (Supplemental Table
S1). This established MYH6 as a candidate gene for this family. A novel
R443P mutation in the head/motor domain of MYH6 was revealed.
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Stage 2: Case-control Association Testing for Rare, Damaging
MYH6 Variants in HLHS
To determine MYH6 association with HLHS, a case-control analysis
for rare, damaging MYH6 variants was performed using a cohort of
190 unrelated HLHS subjects, all of whom had undergone either WES
or WGS, with the Thousand Genomes Phase1v3 database serving as a
control cohort (See supplemental methods, next-generation
sequencing). This revealed the presence of 21 (19 distinct) MYH6
variants (Table 1, Fig. 2B) in 20 (10.5%) HLHS subjects, compared
with the presence of rare, damaging MYH6 variants in only 2.9% of
control subjects (n = 1,063 unrelated individuals). The null hypothesis
that the observed >360% enrichment was due to chance was rejected
(Fisher's exact test for difference in proportions P < 1 × 10−5,
Supplemental Table S1). We further validated this finding by
performing the same test using a larger database, the Exome Variant
Server, National Heart, Lung, and Blood Institute (NHLBI) Gene
Ontology Exome Sequencing Project (ESP), Seattle, WA (URL:
http://evs.gs.washington.edu/EVS/, date accessed February, 2016)
wherein MYH6 was enriched (P < 5 × 10−3) (supplemental methods,
Supplemental Table S1).
Table 1. List of MYH6 variants
Coordinate
(b37)

R/A Domain Exon
(of
39)

Variant Subject PP2 SIFT Inherit
Name

Pop
Freq

23874837

A/T

head

4

Y115N

R0016

0.999 0

de
novo

novel

23872623

C/A

head

10

Q277H

R0735

0.132 0

Mat

0.03%

23870180

C/T

head

13

D383N

07_155 0.986 0

23870173

G/A

head

13

S385L

10_121 0.157 0.04 Mat

23870021

T/C

head

13

M436V

10_121 0.996 0.12 NonMat novel

23869999

C/G

head

13

R443P

07_067 1

0

23868064

T/G

head

15

D588A

11_099 1

0.26 Mat

23865538

G/A

neck

20

R795W

R0023

23863413

CTT/- tail

21

K850-

07_074

23862995

G/A

tail

22

A936V

R0121

Pat

0.02%

23862912

C/A

tail

22

A964S

10_249 0.997 0.07 NA

0.22%

23862912

C/A

tail

22

A964S

09_299 0.997 0.07 NA

0.22%

23859545

C/T

tail

26

R1151Q

07_082 0.937 0.04 NA

novel

23858686

G/A

tail

28

A1298V

09_103 0.65 0.11 NA

0.01%

23858106

G/A

tail

29

T1379M

09_152 0.995 0.06 NA

0.06%

0.998 0
NA

NonPat novel

Pat
Mat

NA NA

0.796 0.1

novel
novel
0.17%
0.01%
novel
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Coordinate
(b37)

R/A Domain Exon
(of
39)

Variant Subject PP2 SIFT Inherit
Name

Pop
Freq

23858106

G/A

tail

29

T1379M

12_093 0.992 0.06 NA

0.06%

23857394

G/T

tail

30

A1443D

11_003 0.885 0.03 NA

novel

23856983

T/A

tail

31

E1503V

12_234 1

novel

23855732

C/T

tail

33

E1584K

09_204 0.889 0

23854153

C/A

tail

35

E1754X

07_026

0.03 Mat
NA

Mat

NA NA

novel
0.01%

23853696
T/C tail
36
K1840R R0300 0.999 0.11 NA
0.02%
Coordinate, start position GRCh37; R, reference allele; A, alternative allele, Subject,
identification number; PP2, PolyPhen score; NA, not available; Inherit, inheritance
pattern; Mat, maternal; NonMat, nonmaternal; Pat, paternal; NonPat, nonpaternal;
Pop Freq, population frequency from ESP 6500 (URL:
http://evs.gs.washington.edu/EVS/, accessed November 2015).

All MYH6 variants in HLHS subjects were confirmed by PCR and
Sanger sequencing, or by RNA-Seq analysis, using a different tissue
source from the same individual. Among the 19 distinct MYH6 variants,
10 were novel, one was a three-base pair in-frame deletion, and one
was a nonsense mutation. One subject demonstrated paternal
inheritance (F MYH6-R443P) wherein the father was also affected with
CHD, and six subjects demonstrated maternal inheritance patterns
(wherein one mother had BAV and five mothers were asymptomatic,
although cardiac anatomy was unconfirmed). In addition, one subject
exhibited a de novo variant and another demonstrated compound
heterozygous inheritance wherein one variant was clearly inherited
from the mother (paternal DNA unavailable). Nearly all (19/20) of the
HLHS subjects were heterozygous carriers, supporting a previous
study suggesting a dominant but incompletely penetrant pattern of
inherited atrial septal defects.33 These data confirmed the association27
of rare, damaging MYH6 variants with HLHS. Odds ratio was calculated
as 4.1 (95% confidence interval 2.3 to 7.4; P < 1 × 10−4).

Stage 3: Transplant-free Survival Analysis
Follow-up data from 72 HLHS subjects (≥6 yr of age) showed
that MYH6 variant carriers (n = 10) had significantly lower cardiac
transplant-free survival than wild-type subjects (n = 62) (P < 1 ×
10−2) (Fig. 3). These data indicate that MYH6 variants demonstrate a
long-term consequence in HLHS pathogenicity (27).
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Fig. 3. Transplant-free survival analysis. Kaplan-Meier survival curve constructed from
72 HLHS subjects. Among these, 10 subjects had a rare MYH6 variant (MUT),
compared with 62 WT subjects. The Breslow (generalized Wilcoxon) statistic evaluated
significance, resulting in rejection of the null hypothesis that these curves are
equivalent (P = 6 × 10−3).

Stage 4: Increased MYH7 Expression in HLHS Tissues with MYH6
Variants
RNA-Seq assessed whether MYH6 variants affected gene
expression in cardiac tissue from HLHS subjects. Transcriptomes were
compared in discarded atrial septal tissue from 10 HLHS subjects, half
of whom had an MYH6 variant, as well as from discarded right
ventricular tissue of six HLHS subjects, half of whom also had an MYH6
variant. Tissues were matched pair-wise according to age, and when
possible, as well as to sex and aortic and mitral valve anatomy (Fig.
4A, Supplemental Table S2). Although no significant change in MYH6
transcript levels was detected in HLHS tissues containing MYH6
variants, 22 other genes were differentially expressed (Supplemental
Fig. S1, Supplemental Table S3). Among these cardiac troponin T2
(TNNT2), myosin heavy chain 7 (MYH7), skeletal muscle alpha actin 1
(ACTA1), and myosin light chain 2 (MYL2) (all which are components
of the contractile apparatus), were significantly upregulated (>3- to
12-fold, P ≤ 5 × 10−3). MYH7, the major myosin in human ventricle
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and the closest paralog of MYH6, was increased by almost 350%
relative to tissues in HLHS subjects containing wild-type MYH6 (Fig.
4A, Supplemental Table S3; P < 1 × 10−3). Upregulation of MYH7
expression from the five pairs of atrial samples was confirmed by
quantitative RT-PCR (supplemental methods, myh7 quantitative rtpcr). To assess whether increased MYH7 expression extended to the
protein level, levels of β-MHC protein in the same pair-matched atrial
septal and right ventricular discards were compared by Western
blotting; this revealed that β-MHC was substantially increased in HLHS
subjects with MYH6 variants (generalized linear model/ANOVA, +62%,
± 0.15 SE, P < 1 × 10−3) (Fig. 4B, Supplemental Table S4).

Fig. 4. Pairwise analysis of gene expression of MYH7 in HLHS patients with and
without MYH6 variants. A: gray-shaded and black bars denote HLHS patients with and
without MYH6 variants, respectively. The annotation within each gray bar indicates the
amino acid change resultant from each MYH6 mutation. Paired bars on the left and
right side of the figure, respectively, indicate ventricular and atrial septal samples.
Subject information is available in Supplemental Table S2. Sample number, sex status
(male or female), and age (m, month; d, day; y, year) are denoted in the x-axis label.
MYH7 expression is significantly increased (346%) in HLHS patients with an MYH6
mutation (P < 1 × 10−3, Supplemental Table S3). TPM, transcripts per million. B:
Western blot showing increased β-MHC protein in the right ventricle and atrial septum
of HLHS patients with an MYH6 variant. B, top: representative Western blot selected
from 5 technical replicates of 4 pairs of patient samples; pairings are denoted on the
x-axis. The entire immunoblot is shown in Supplemental Fig. S2. B, bottom:
densitometric analysis of β-MHC levels normalized to GAPDH, reflecting the average of
5 replicate determinations performed on the 4 tissue pairs shown in B, top. Statistical
analysis of the aggregate data representing the 4 pairs was statistically significant P <
1 × 10−3, generalized linear model/ANOVA, 62%, ± 0.15 SE.
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Stage 5: Increased MYH7 Expression and Defective
Differentiation in iPSC-derived Cardiomyocytes from HLHS
Subjects with MYH6 Variants
To determine whether increased MYH7 expression is
phenocopied in cardiomyocytes derived from iPSCs, iPSC lines were
generated from dermal fibroblasts of family F MYH6-R443P. Following
cellular expansion and verification of pluripotency, iPSCs representing
the proband and an unaffected parent were induced to undergo
cardiomyogenic differentiation as recently described21 (depicted in Fig.
5A), during which cultures of cardiomyogenic cells were removed for
RNA-Seq determinations on the differentiation days shown in Fig. 5D.
As anticipated,21 MYH7 transcription was first detected on
differentiation day 5, at which stage similar levels of MYH7 transcripts
were seen in cardiomyocytes representing the proband and its
unaffected parent. On day 8, although substantial increases in MYH7
expression were seen in cardiomyocytes from both individuals, the
level of expression in proband cardiomyocytes was ∼2.5-fold greater
than that observed in myocytes from the unaffected parent. Increased
MYH7 expression in proband cardiomyocytes was confirmed by
quantitative PCR performed on two independent iPSC lines from each
subject (Fig. 5E, left). In addition, the efficiency of cardiomyogenic
differentiation was significantly reduced in the HLHS proband's
cardiomyocytes, as determined by α-MHC immunostaining (Fig. 5B)
and flow cytometry assessments of percent cTnT-positive cells (Fig.
5C). All of these findings were recapitulated in iPSC-derived
cardiomyocytes from an unrelated HLHS family that contained a
different MYH6 mutation, which was identified in the CHD Tissue Bank
(F MYH6-D588A: Fig. 5E, right, and Supplemental Fig. S4). Finally, we
evaluated sarcomere structure in iPSC-derived cardiomyocytes at later
stages of differentiation (days 62–68), observing that, compared with
the unaffected parent, sarcomeres were substantially disorganized in
both the affected parent and the proband of family F MYH6-R443P
(Fig. 6).
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Fig. 5. Increased MYH7 expression in iPSC-derived cardiomyocytes from probands in 2
HLHS families. A: scheme for differentiating cardiomyocytes with small molecule Gsk3
inhibitor (CHIR99021) and wnt inhibitor (IWP). B: immunostaining of α-MHC at day 10
showing defective cardiomyogenesis in iPSCs from the HLHS proband and affected
parent (carrier father) of family F MYH6-R443P. C: flow cytometry of cells cultured in
parallel with those in B, showing decreased percentages of cardiac troponin T (cTnT)positive cells at day 10. Data were compiled from 3 iPSC lines derived from each
individual. The P values were calculated by Student's t-test (2-tailed, equal variance);
vertical lines = ± SE. D: RNA-Seq showing MYH7 expression in iPSC-derived
cardiomyocytes (CMs) from family F MYH6-R443P at differentiation day 8. Proband
bars represent the average of 2 cell lines; vertical lines = range. Unaffected parent
bars represent values from single cell line. E, left: quantitative PCR showing increased
MYH7 expression in the HLHS proband of family F MYH6-R443P. E, right: a similar
result from iPSC-derived cardiomyocytes of a separate HLHS family (F MYH6-D588A).
Bars represent the average of triplicate cultures evaluated in 2 independent iPSC lines
(n = 6). The P values were calculated by Student's t-test (2-tailed, equal variance);
vertical lines = ± SE. Additional iPSC analysis from family F MYH6-D588A is shown in
Supplemental Fig. S4.

Discussion
Among hypotheses explaining left ventricle hypoplasia in HLHS
are that 1) reduced blood flow due to valvular atresia/stenosis alters
ventricular preload with consequent dysmorphology16 and that 2)
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defective expansion and/or differentiation of cardiomyocytes results in
dysmorphology and dysfunction.8 While the results reported here can
be reconciled with both hypotheses, our observations that iPSCderived cardiomyocytes from the affected parent and proband of
families that carry selected MYH6 variants undergo poor
cardiomyocyte differentiation followed by poor sarcomere organization
suggest that HLHS etiology is cardiomyocyte autonomous (Fig. 6). In
either event, the data demonstrate that rare MYH6 variants, which are
present in 10.5% of HLHS cases, have pathogenic consequences.

Fig. 6. Dysmorphic sarcomeres in CMs derived from iPSCs reprogrammed from the
HLHS proband and its affected parent. A: α-actinin immunostaining of mass cultured
CMs at differentiation day 65. B: comparative sarcomere organization in individual CMs
isolated from the cultures shown in A and subcultured at low density. A minimum of
100 isolated CMs representing each individual were judged to contain dysmorphic
sarcomere organization if most of the myocyte area displayed blurred staining in which
sarcomeric ladders contained punctate or truncated deposits of α-actinin ladders,
rather than the relatively crisp and elongated ladders with relatively wide Z-bands that
characterize MYH6+/+ cells. C: data were compiled from quadruplicate dishes
representing each iPSC line (1 line from each parent; 2 lines from the proband)
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evaluated during a single determination. The P values were calculated by Student's ttest (2-tailed, equal variance); vertical lines = ± SE.

We unexpectedly found that expression of a subset of cardiac
contractility genes was increased in the presence of MYH6 variants.
This possibly represents an adaptive mechanism, similar but not
identical to that which occurs in the failing heart muscle.35 Most
remarkably, the presence of MYH6 variants is accompanied by strongly
increased expression of MYH7, in both atrial and ventricular tissues of
HLHS subjects (Fig. 4). In addition to confirming the increased
expression of MYH7 in HLHS tissues containing MYH6 variants (Fig. 4,
A and B), the findings in Fig. 5, D and E, that increased MYH7
expression is phenocopied in cardiomyocytes from iPSCs in two
separate families, indicate that HLHS etiology can be investigated at
the earliest stages of cardiomyogenesis using this in vitro disease
model.
Altered contractility has been proposed as an etiologic
mechanism in CHD.18 The increase in MYH7, which is considered as the
“slow twitch isoform,” may adaptively reduce energy requirements in
the hypoplastic myocardium because β-MHC (MYH7) has relatively low
ATPase activity.31 It follows that maximal shortening velocity and peak
power would be altered, resulting in hypocontractility. Because MYH6
is the predominant atrial isoform, it is plausible that atrial
hypocontractility due to mutated MYH6 impedes the flow of fetal blood
from the right atrium to the left atrium and through the mitral valve,
resulting in limited filling of the left ventricle. This scenario, which is
consistent with both the cardiomyocyte-autonomous and flow
hypotheses, may explain underdevelopment of the mitral valve, left
ventricle, and aortic arch, all of which are hallmarks of HLHS. Indeed,
previous studies have shown that mutation of myh6 in zebrafish and
the subsequent disruption of atrial function have a profound effect on
ventricular morphogenesis and atrioventricular valve formation.2,19
Although examination of the effect of MYH6 variants on
contractile power was beyond the scope of this study, it is noteworthy
that variants were observed across all functional domains of α-MHC. In
particular, seven mutations were noted in the head/motor domain,
including four within an exon 13 “hotspot” that includes R443P (Fig.
3). Alterations in the α-MHC head/motor region have been shown to
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impact stiffness that results in diastolic dysfunction.20 Also, because
the head/motor domain contains binding sites for ATP and actin,
variants may induce conformational changes that compromise actinmyosin association. Although only one mutation was found in the neck
region, 11 were noted in the coiled-coil/tail region, among which half
were located in the domain that interfaces with myosin light chain; in
this regard it may be relevant that MYL2, which is required for
cardiomyocyte differentiation in the murine heart,5 like MYH7, also
exhibits increased expression in HLHS patients who carry MYH6
variants (Fig. 4 and Supplemental Table S3). It is also plausible that
alterations in the α-MHC tail cause reduced power, as mutations in the
tail of homolog β-MHC reportedly distort helicity of the coiled-coil
region.42
Previous studies have found that failing hearts, such as those
from cardiomyopathy patients, exhibit decreased levels of MYH6
mRNA,25,26,30 with concomitantly increased expression of MYH7.34 It is
well known that treatment of cardiomyopathy with β-blockers
improves myocardial function and increases survival, an effect that
likely results from decreased adrenergic stimulation.9 However, βblockers also distort the expression of myocardial genes, most
remarkably depressing levels of β-MHC concomitant with the
restoration of fast-contracting α-MHC fibers,22 resulting in improved
cardiac function.25 While acknowledging the complexity of drug-gene
interactions, these findings, when superimposed on the results
reported here, invite speculation that β-blocker therapy, with or
without recently developed cardiac myosin activation therapies,28 may
be useful for treating HLHS subjects who carry pathogenic MYH6
variants. Ongoing work using iPSC-derived cardiomyocytes will
determine the responsiveness of myocytes containing pathogenic
MYH6 variants to pharmaceutical agents including β-blockers and
myosin activation drugs.

Limitations
In case-control association analyses, it is desirable to select
appropriate control cohorts including those that share ethnic, sex, and
age composition. In this study, the publicly available Thousand
Genomes Phase 1v3 database was used as a control cohort against
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whole exomes and genomes of HLHS patients. The controls often had
low read-depth and were not imputed; therefore, rare variants may be
underrepresented. However, if missed variants exist uniformly across
the control genomes, the corresponding decrease in signal-to-noise
would not impact our finding that MYH6 was among the most
overrepresented of the 20 candidate genes identified through pedigree
analysis. We mitigate genome-wide false positives by only
investigating the 20 candidate genes from the pedigree analysis and
by replicating enrichment against the larger exome database, NHLBI's
ESP.
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